Answers are grounded in this paper and cite their sources.
MicroRNAs have become central players in the process of finding and implementing novel therapeutic strategies for the overcoming of the cancer associated heterogeneous effects.Their ability to target multiple coding genes in order to influence and regulate entire signaling networks and also their differential expression between healthy and malignant cell is nowadays tackled in preclinical studies that enroll models of human cancers.The main approaches consist in the inhibition of oncogenic miRNAs that are usually overexpressed in transformed cells and also the re-expression of the tumor suppressor ones that are characterized by a downregulated expression pattern.No matter the strategy, it is vital to choose wisely the targeted sequence in order to achieve global cancer inhibitory effects, where key players that direct phenotypically transformations sustain numerous miRNA signatures.As important is also the therapeutic strategy that needs to be validated in terms of both efficiency and safety in order to avoid installation of secondary pathological conditions.
No takes yet. Share an insight, caveat, or question.
Gulei et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: